STUTTGART, Germany I September 08, 2019 I La Merie Publishing announced the release of its newest report “RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective”. Since 2017, investors and Big Pharma companies have poured nearly US$ 1 bln to finance emerging companies with enabling technologies for RNA biology and for discovering small molecules against RNA as a drug target.

RNA as a target holds the promise of dramatically increasing the pool of druggable targets as compared with conventional protein targets. RNA as a therapeutic drug has validated this concept, but has limitations such as delivery issues and toxicity. Thus, small molecules targeting RNA is an attractive concept for the pharmaceutical industry.

The report describes and analyzes from an industry perspective with a view on emerging technology companies regarding their founding background, financial history, technological capabilities, target and indication selection and most advanced lead compounds. Four approaches to target RNA with small molecules are separately examined:

  • mRNA translation regulation;
  • RNA splicing modification
  • Direct RNA targeting; and
  • Epitranscriptomics, i.e. indirectly targeting RNA via the proteins it is interacting with.

Albeit different, the four approaches are complementary, but the analysis shows differences in maturity and preferences of pharma partners and investors.

Big Pharma also has in-house R&D activities to discover small molecules targeting RNA complemented with technology collaborations and support of emerging technologies via their venture capital. The report describes the stakes Big Pharma holds in the field and the level of participation.

The report can be acquired at La Merie Publishing’s online store at

About La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports as well as competitor analysis reports and target pipeline lists, the latter two in a tabulated format with structured listings of industry-relevant data. La Merie Publishing products can be purchased in our new online store at and at selected Resellers.

The focus of our products is directed towards therapeutic biologics, such as antibodies, proteins, peptides, vaccines and gene & cell therapy. We pay special attention to biosimilar antibodies and proteins, antibody drug conjugates, bispecific antibodies, TCR & CAR engineered antibodies, mRNA vaccines & therapeutics, oncolytic viruses and immuno-oncology in general.

To leverage our expertise and knowledge accumulated in our in-house database, we offer custom report preparation services for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest for our clients.

SOURCE: La Merie Publishing